Abiopharma

Events and transactions

Register of shareholders - amendment of report

Incyte präsentiert neue positive 54-Wochen-Daten zu Povorcitinib bei Hidradenitis suppurativa auf der Jahrestagung 2026 der American Academy of Dermatology (AAD)

Incyte maakt nieuwe positieve, recent bekendgemaakte gegevens over een periode van 54 weken bekend voor povorcitinib bij hidradenitis suppurativa tijdens de jaarlijkse bijeenkomst van de American Academy of Dermatology (AAD) in 2026

Incyte annuncia gli ultimi nuovi dati positivi ottenuti in 54 settimane su povorcitinib nellidrosadenite suppurativa al Meeting annuale 2026 della American Academy of Dermatology (AAD)

Incyte anuncia nuevos datos positivos de última hora a las 54 semanas sobre el povorcitinib para la hidradenitis supurativa en el 2026 American Academy of Dermatology (AAD) Annual Meeting

The company’s liability balance as of 31.12.25, by maturity dates

Periodic and annual report for 2025

A meeting that was convened for March 24, 2026 is postponed to April 5, 2026

KD Investors Have Opportunity to Lead Kyndryl Holdings, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm